SG/CALL/VERTEX PHARMACEUTICALS/300/0.1/20.09.24 | Delayed Deutsche Boerse AG 04:41:14 20/06/2024 pm IST | ||
| 15.78 EUR | +1.22% |
|
| Current month | +5.41% | ||
| 1 month | +12.32% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 20/24/20 | 15.78 | +1.22% |
| 19/24/19 | 15.59 | -3.47% |
| 18/24/18 | 16.15 | -3.00% |
| 17/24/17 | 16.65 | -4.03% |
| 14/24/14 | 17.35 | +2.30% |
Delayed Quote Deutsche Boerse AG
Last update June 20, 2024 at 04:41 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SQ80E9 |
| ISIN | DE000SQ80E90 |
| Date issued | 13/02/2023 |
| Strike | 300 $ |
| Maturity | 20/09/2024 (93 Days) |
| Parity | 10 : 1 |
| Emission price | 5.47 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 17.77 € |
|---|---|
| Lowest since issue | 4.71 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
467.3
USD
Average target price
463.4
USD
Spread / Average Target
-0.83%
- Stock Market
- Warrants
- Warrant
